Pope Leo XIV's lung cancer diagnosis has renewed attention on non-smokers, who can face delayed diagnoses despite risks including radon, genetics, second-hand smoke and pollution.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways The main tests for kidney disease are an estimated glomerular filtration rate (eGFR) blood test and a urine albumin-to-creatinine ratio (UACR) ...

In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.

He felt healthy but routine blood tests revealed declining kidney function. His case highlights the silent progression of ...

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, ...

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

AstraZeneca announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal ...

Hello everyone, how are you doing? It's Tamako! 🐱💊"Since the creatinine isn't high, is this dosage okay?""If the eGFR is ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated lung cancer ...